Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

Peter Kraft¹, Tobias Schwarz¹, Joost C. M. Meijers², Guido Stoll¹, Christoph Kleinschnitz¹

¹ Department of Neurology, University of Wuerzburg, Wuerzburg, Germany, ² Departments of Vascular Medicine and Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Abstract

Background: Thrombus formation is a key step in the pathophysiology of acute ischemic stroke and results from the activation of the coagulation cascade. Thrombin plays a central role in this coagulation system and contributes to thrombus stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa). TAFIa counteracts endogenous fibrinolysis at different stages and elevated TAFI levels are a risk factor for thrombotic events including ischemic stroke. Although substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the consequences of TAFI inhibition in animal models of cerebral ischemia are still lacking. In the present study we analyzed stroke development and post stroke functional outcome in TAFI⁻⁻ mice.

Methodology/Principal Findings: TAFI⁻⁻ mice and wild-type controls were subjected to 60 min transient middle cerebral artery occlusion (tMCAO) using the intraluminal filament method. After 24 hours, functional outcome scores were assessed and infarct volumes were measured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices. Hematoxylin and eosin (H&E) staining was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by immunoblot. Infarct volumes and functional outcomes did not significantly differ between TAFI⁻⁻ mice and controls (p=0.05). Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. TAFI deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO.

Conclusion: Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after ischemic brain challenge.

Introduction

The majority of ischemic strokes are caused by thromboembolic occlusion of brain arteries [1]. Consequently, thrombolysis using recombinant tissue plasminogen activator (rt-PA) is an established therapy during the first 4.5 h after stroke onset but efficacy is only moderate at best and about 90% of all stroke patients must be excluded from rt-PA treatment due to numerous contraindications [2,3]. Current strategies for secondary stroke prevention comprise platelet inhibitors and long-term anticoagulation with warfarin in the case of cardioembolic stroke. However, as a major drawback these substances are all associated with increased bleeding complications [4]. Hence, there is a significant unmet medical need for more effective and safer therapies in patients with acute or recurrent stroke.

Two distinct pathways of blood coagulation can initiate the formation of a fibrin thrombus, the extrinsic and the intrinsic pathway [5]. Both are activated in a “waterfall-like” manner involving a series of trypsin-like serine proteases such as the tissue factor (TF)/FVIIa complex (extrinsic pathway) or FXII (intrinsic pathway) finally culminating in the generation of thrombin [6]. Thrombin is considered a key component of blood coagulation [7]: It can initiate clotting by activating FV and FVIII, platelets, and platelet-bound FXI. Moreover, the conversion of prothrombin to thrombin by FXa and FVa further propagates coagulation. Finally, thrombin is critically involved in thrombus stabilization via thrombin-dependent FXIIIa-driven cross-linking of the fibrin network and activation of thrombin-activatable fibrinolysis inhibitor (TAFI). Activated TAFI (TAFIa) is part of a highly dynamic system that downregulates fibrinolysis. Activation occurs with high doses of thrombin in the absence of thrombomodulin in the setting of the intrinsic pathway of coagulation, or with low concentrations of thrombin in complex with thrombomodulin [8]. TAFI acts through removing carboxy-terminal lysine residues of partially degraded fibrin, leading to elimination of plasminogen binding sites, inhibition of plasminogen activation and impaired fibrinolysis [8,9]. Several polymorphisms in the human TAFI gene have been identified that influence TAFI antigen levels [10,11] and elevated serum TAFI is a risk factor for deep vein thrombosis [12] and coronary artery disease [13]. In contrast, available data
on the role of TAFI in cerebral ischemia are limited but its function as an endogenous fibrinolysis inhibitor and the observation that TAFI-deficient (TAFI<sup>−/−</sup>) mice do not show abnormal bleeding [14,15] renders TAFI an attractive therapeutic target in different thromboembolic disorders including stroke. In the present study we assessed stroke development, intracerebral fibrin formation and post stroke functional outcome in TAFI<sup>−/−</sup> mice.

**Results**

The middle cerebral artery (MCA) was occluded with a silicon-coated filament for 60 min (transient middle cerebral artery occlusion, tMCAO) to induce focal cerebral ischemia in mice [16,17]. After advancing the filament to the origin of the MCA the decrease in regional cerebral blood flow (rCBF) was similar between wild-type mice and TAFI<sup>−/−</sup> mice (8.3±4.2% vs. 10.2±1.5% of baseline levels; p>0.05) (Figure 1A). Ten minutes after removal of the filament (reperfusion) rCBF in the MCA territory was reconstituted to ~70% of baseline levels and again did not significantly differ between the two mouse groups (69.5±8.3% vs. 73.4±10.1% of baseline levels; p>0.05) (Figure 1A). These findings exclude that TAFI<sup>−/−</sup> mice show preformed rCBF alterations related to the genotype and prove that MCA occlusion and reperfusion were sufficient in our model. Along these lines, no aberrations in the cerebral vasculature were observed in TAFI-deficient mice as assessed by transcardial ink perfusion (Figure 1B).

As a next step, we determined infarct sizes and the extent of neuronal damage in TAFI<sup>−/−</sup> mice and controls. 24h after tMCAO no significant differences in infarct volumes were observed between the two groups as revealed by 2,3,5-Triphenyltetrazoliumchloride (TTC) staining and successive infarct planimetry (91.4±21.5 mm³ vs. 95.6±27.2 mm³; p>0.05) (Figure 2A).

In line with these findings, H&E staining confirmed widespread ischemic neurodegeneration in both groups which regularly expanded to the basal ganglia and the neocortex (Figure 2A).

Figure 1. rCBF and the anatomy of the cerebral vasculature do not differ between TAFI<sup>−/−</sup> mice and controls. (A) Determination of regional cerebral blood flow (rCBF) using Laser Doppler flowmetry before the occlusion of the middle cerebral artery (baseline), 10 min after the occlusion (ischemia) and again 10 min after the removal of the filament (reperfusion) in TAFI<sup>−/−</sup> mice and wild-type controls (n = 4/group). No significant differences in rCBF were observed between the two groups. 1-way ANOVA, Bonferroni post hoc test. (B) Assessment of the cerebral vasculature in wild-type and TAFI<sup>−/−</sup> mice. A complete Circle of Willis (white arrows) was identified in all animals studied and the distribution of the MCA trunk and branch appeared to be anatomically identical among the genotypes.

doi:10.1371/journal.pone.0011658.g001
Figure 2. TAFI deficiency does not improve outcome after experimental stroke in mice. Infarct size and functional outcome in TAFI−/− mice and controls (WT, wild-type) 24h after 60 min transient middle cerebral artery occlusion (tMCAO). (A) (top) Representative 2,3,5-Triphenyltetrazolium chloride (TTC)-stained coronal brain sections from the two animal groups. Ischemic infarctions appear white and regularly include the neocortex and basal ganglia as confirmed by hematoxylin and eosin (H&E) staining (bar represents 250 μm, dotted white line indicates the border between the cortex and the basal ganglia). (bottom) Infarct volumes on day 1 after tMCAO in TAFI−/− mice and controls as determined by planimetry (n = 11–12/group). Non-parametric Mann Whitney test. (B) Neurological Bederson score and grip test score on day 1 after tMCAO in TAFI−/− mice and controls. In line with the results on infarct volumes, no significant functional differences became apparent. Non-parametric Mann Whitney
Detailed analysis of the functional status also showed no significant differences between TAFI−/− mice and controls for the grip test assessing motor function and coordination (3.0 ± 1.3 vs. 2.4 ± 0.5; p = 0.05) and for the Bederson score assessing global neurological function (2.7 ± 1.1 vs. 3.2 ± 0.6; p = 0.25) (Figure 2B). Finally, thrombus formation, i.e., deposition of fibrin(ogen) within the infarcted cortices of TAFI−/− mice and wild-type mice was visualized by Western blot (Figure 2C). While fibrinogen immunoreactivity was largely absent in the non-ischemic contralateral hemispheres, a strong signal was detected in the ischemic cortices which however, did not differ between the groups.

Discussion

This is the first study examining TAFI−/− mice in an in vivo model of focal cerebral ischemia. Contrary to our initial hypothesis, TAFI deficiency did not protect from acute ischemic stroke.

Existing data strongly support the concept that TAFI acts as a molecular link between coagulation and fibrinolysis [18]. TAFIa restrains fibrinolysis through eliminating plasminogen binding sites from degraded fibrin and direct inhibition of plasminogen activation [8,9]. Given this prothrombotic mechanism of TAFI action we assumed that TAFI deficiency would increase fibrinolysis and consequently, ameliorate ischemic brain damage after tMCAO in mice, a model in which microvascular thrombosis and fibrin deposition are key pathophysiological steps [16,19,20]. Another observation indicative for TAFI being an attractive pharmacological target to treat or prevent thromboembolic disorders is the absence of excess bleeding in TAFI−/− mice [15]. Such a safe therapy would be particularly advantageous for the treatment of acute ischemic stroke, where the conventional thrombolytics and anticoagulants used are inevitably associated with increased bleeding-related morbidity and mortality.

Whether endogenous fibrinolysis in TAFI−/− mice is indeed enhanced under pathophysiological conditions in vivo is still under debate. Nagashima and co-workers found no differences in occlusion time in TAFI-deficient mice compared to controls after either artificial arterial or venous injury [15]. Moreover, TAFI deficiency neither improved the survival rate after thrombin-induced pulmonary thromboembolism nor in an endotoxin model of disseminated intravascular coagulation [15]. In contrast, plasma clots produced from the same knockout mice lyed faster in vitro and less fibrin was retained in the lungs of TAFI-deficient mice after batroxobin-induced pulmonary embolism in another study [21]. We here further extend these findings by demonstrating that TAFI deficiency has no major beneficial effect on intracerebral fibrin formation and neuronal damage after ischemic brain challenge.

Whether our results also apply to the human situation needs further clarification. Here, plasma TAFI levels were increased in patients suffering from acute ischemic stroke and correlated with stroke severity in several retrospective studies [22–26]. A recent study could establish an association between the Thr325Hc polymorphism of TAFI with the incidence and age of stroke onset [27]. However, contradictory reports identifying low TAFI concentrations as a risk factor for stroke and myocardial infarction have also been published [28–30]. While excessive TAFI levels could foster thrombosis by inducing a hypofibrinolytic state, the inverse association between reduced TAFI concentrations and higher numbers of thrombotic events might by a consequence of enhanced inflammation since the anti-inflammatory properties of TAFI are well established [28,31–33]. The finding that C-reactive protein (CRP) antigen levels paralleled the course of TAFI both in the acute (increase) and later phase (decrease) of ischemic stroke further support an association between hemostasis and inflammation in this disease [25].

Only recently, the safety and efficacy of the direct thrombin inhibitor dabigatran in preventing systemic embolism including stroke in patients with atrial fibrillation has been demonstrated [34, comment in 35]. Interestingly, dabigatran enhances clot susceptibility to fibrinolysis at least partially by TAFI-dependent mechanisms in vitro [36]. In line with these findings, TAFIs significantly affected the efficacy of rt-PA and vessel recanalization in patients undergoing thrombolysis after acute ischemic stroke [37] although in vitro experiments suggested that the clot lysis rate by pharmacological concentrations of rt-PA is not altered by TAFIs [38].

In summary, despite the definite broad influence of TAFI in the coagulation-fibrinolysis system, our present study could not demonstrate a beneficial effect of TAFI deficiency on clot formation and successive neuronal degeneration after tMCAO in mice. Whether this also applies to other thrombus-dependent models of acute ischemic stroke needs to be further established.

Materials and Methods

Animals

A total of 38 mice were used in this study. Animal experiments were approved by legal state authorities (Bezirksregierung of Unterfranken, approval number 54-2531.01-25/06) and conducted according to the recommendations for research in basic stroke studies [39]. TAFI−/− mice were described previously [40] and backcrossed more than 10 times to C57Bl/6 background. Extensive haematological characterization of TAFI−/− mice can be found elsewhere (review in [14]). Wild-type (WT) C57Bl/6 animals were obtained from Harlan Winkelmann (Borchen, Germany) and used as controls. Male TAFI−/− and WT mice were aged 6–8 weeks.

Murine stroke model

Focal cerebral ischemia was induced by 60 min tMCAO as described [16,17]. Mice were anesthetized with 2.5% isoflurane (Abbott, Wiesbaden, Germany). Following a midline skin incision in the neck, the proximal common carotid artery and the external carotid artery were ligated and a standardized silicon rubber-coated 6.0 nylon monofilament (60SPPK10; Doccol Corp., Redlands, CA, USA) was inserted and advanced via the right internal carotid artery to occlude the origin of the right MCA. Operators were blinded to the genotype and operation time per animal did not exceed 15 minutes. The intraluminal suture was left in situ for 60 minutes. Then animals were re-anesthetized and the occluding monofilament was withdrawn to allow reperfusion.

The exclusion criteria were as follows:

a) Death within 24 h after tMCAO
b) Subarachnoid hemorrhage (as macroscopically assessed during brain sampling)

Bederson score = 0 (24 h after tMCAO)
Two animals (14.3%) in the wild-type group and one animal (7.7%) in the in TAFI−/− group met at least one of these exclusion criteria and were withdrawn from the study.

**Determination of infarct size and histology**
Edema-corrected infarct volumes were quantified by planimetry from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain sections 24 h after ischemic stroke as described in [16,17]. For morphological assessment, paraffin embedded brains were stained with hematoxylin and cosin (H&E).

**Assessment of functional outcome**
24 h after tMCAO the modified Bederson score [41] was used to determine global neurological function according to the following scoring system: 0, no deficit; 1, forelimb flexion; 2, decreased resistance to lateral push; 3, unidirectional circling; 4, longitudinal spinning; 5, no movement. Motor function and coordination were evaluated by the grip test [42]. For this test, the mouse was placed midway on a string between two supports and rated as follows: 0, falls off; 1, hangs onto string by one or both forepaws; 2, as for 1, and attempts to climb on string; 3, hangs onto string by one or both forepaws plus one or both hindpaws; 4, hangs onto string by fore- and hindpaws plus tail wrapped around string; 5, escape (to the supports). Rating was performed in a blinded manner.

**Laser-Doppler flowmetry**
Laser-Doppler flowmetry (Moor Instruments, Axminster, U.K.) was used in some animals (n = 4/group) to monitor rCBF in the MCA territory (6 mm lateral and 2 mm posterior from bregma) [43].

**Assessment of the cerebral vasculature**
For assessment of the cerebral vasculature WT and TAFI−/− mice (n = 3/group) were deeply anesthetized with CO2 and transcardially perfused with 4% paraformaldehyde (PFA), followed by 3 ml black ink diluted in 4% PFA (1:5 v/v). Brains were incubated with the primary antibody at 4°C overnight at the following dilutions: anti-Fibrinogen pAb 1:500 (Acris Antibodies) and anti-Actin mAb 1:10,000 (DiaNovo). After a washing step with TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20), membranes were incubated for 1 hour with HRP-conjugated donkey anti-rabbit IgG (for Fibrinogen) or donkey anti-mouse IgG (for Actin) at a dilution of 1:5000 and were finally developed using ECLplus (GE Healthcare).

**Statistics**
Data are expressed as mean ± standard deviation (SD). For statistical analysis, PrismGraph 4.0 software package (La Jolla, CA, USA) was used. Infarct volumes and neurological scores were analyzed using the non-parametric Mann Whitney test. Laser Doppler flowmetry data were compared by Bonferroni-corrected 1-way ANOVA. P-values <0.05 were considered to be statistically significant. For power and type-II (beta) error calculations on infarct volumes GraphPad StatMate 2.0 software package was used (GraphPad Software, Inc, La Jolla, CA, USA). The mean infarct volume at day 1 after 60 min tMCAO in C57Bl/6 WT mice was 96 ± 27 mm³ and in TAFI−/− mice 91 ± 22 mm³ (Fig. 2A). We assumed that a ± 35% reduction (Δ = 34.0 mm³) of infarct size would be of biological relevance [44,45]. The significance level (alpha) was chosen as 0.05 (two-tailed). Given these premises the power to detect a difference between means of infarct volumes of 34.0 mm³ was 90% in our study (type-II [beta] error: 10%) which is a favourable result compared to many other experimental stroke studies [39,46].

**Acknowledgments**
We thank Melanie Glaser and Daniela Urlaub for excellent technical assistance.

**Author Contributions**
Conceived and designed the experiments: PK, CK. Performed the experiments: PK, TS. Analyzed the data: PK, TS, CK. Contributed reagents/materials/analysis tools: JCM. Wrote the paper: PK, TS, JCM, GS, CK.

**References**
1. Edwards MT, Murphy MM, Geraghy JJ, Wull JA, Konzen JP (1999) Intravascular Cerebral Thrombolysis for Acute Ischemic Stroke in a Community Hospital. Am J Neuroradiol 20: 1682–1687.
2. Bouskaert M, Lemmens R, ThijsVincent (2009) Reducing prehospital delay in acute stroke. Nature Reviews Neurology 5: 477–483.
3. van den Berg JSP, de Jong G (2009) Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital. Acta Neuro Scand 120: 157–160.
4. Hankey GJ, Eikelboom J (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 9: 273–284.
5. Davie EW, Ramhoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145: 1310–1312.
6. Maclaurine RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202: 496–499.
7. Martí-Fàbregas J, Mateo José (2009) Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke. Cerebrovasc Dis 27: 111–119.
8. Mosnier LO, Bouma BN (2006) Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 26: 2454–2453.
9. Bouma BN, Meijers JC (2003) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxy- peptide B, procarboxy- peptide B). J Thromb Haemost 1: 1566–1574.
10. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, et al. (2001) Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97: 2551–2556.
11. Franco RF, Fagundes MG, Meijers JC, Reitman PH, Loureiro D, et al. (2001) Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86: 510–517.
12. Van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95: 2853–2859.
13. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, et al. (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84: 364–368.

14. Morser J, Gabarra EC, Myles T, Leung LL (2010) What has been learnt from the Thrombin Activatable Fibrinolysis Inhibitor (TAFI)-deficient mouse? J Thromb Haemost. In press.

15. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, et al. (2002) Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 109: 101–110.

16. Kleinschmitz C, Stoll G, Benduzsz M, Schuh K, Pauer HU, et al. (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203: 513–518.

17. Bernal-Enroz A, Braun A, Kraft R, Kleinschmitz C, Schlummman TH, et al. (2009) STIM2 regulates capacitative Ca2+ entry in neurons and plays a key role in hypoxic neuronal cell death. Sci Signal 2: ra67.

18. Boffa MB, Koschinsky ML (2007) Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clinical Biochemistry 40: 431–442.

19. Kleinschmitz C, Pougazova M, Pfann M, Bendszus M, Nieswandt B, et al. (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 115: 2323–2330.

20. Stoll G, Kleinschmitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112: 3553–3562.

21. Mao SS, Holahan MA, Bailey C, Wu G, Colussi D, et al. (2005) Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul Fibrinolysis 16: 407–415.

22. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, et al. (2003) Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34: 2387–2391.

23. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Saén J (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34: 1039–1040.

24. Leebeek FWG, Van Gool MPJ, Guimaraes AHC, Brouwers GJ, De Maat MPM, et al. (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3: 2211–2218.

25. Roote E, Wallen H, Antovic A, von Arbin M, Kapounides G, et al. (2007) Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis 18: 365–370.

26. De Bruijne EL, Gils A, Guimaraes AH, Dippel DW, Deckers JW, et al. (2009) The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 7: 919–927.

27. Kozian DH, Lorenz M, Marz W, Cousin E, Mace S, et al. (2010) Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb Haemost 103: 976–983.

28. Meltzer ME, Doiggen CJM, de Groot PG, Meijers JCM, Rosendaal FR, et al. (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94: 811–818.

29. Johan-Vague I, Morange PE, Aubert H, Henry M, Alllaud MF, et al. (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22: 867–873.

30. Brouns R, Heylen E, Willems JLA, Schoonraad J, De Swolfe D, et al. (2010) The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 8: 75–80.

31. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, et al. (2003) Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278: 51059–51067.

32. Leung LL, Nishimura T, Myles T (2008) Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 632: 61–69.

33. Swaisgood CM, Schmitt D, Eaton D, Flow EF (2002) In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 110: 1275–1282.

34. Connolly SJ, Ezekowicz MD, Yusuf S, Eikelboom JH, Oldgren J, et al. (2006) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 356: 1139–1151.

35. Eikelboom JW, Wallentin L, Yusuf S, Ezekowicz MD, Reilly PA, et al. (2010) Does dabigatran improve stroke-prevention in atrial fibrillation? J Thromb Haemost. In press.

36. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M (2010) Dabigatran enhances clot susceptibility to fibrinolysis by TAFI-dependent and independent mechanisms. J Thromb Haemost 8: 1–9.

37. Brouns R, Heylen E, Schoonen J, Willems JLA, Kummer J, et al. (2009) Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin Neurol Neurosurg 111: 165–170.

38. Colucci M, D’Aprile AM, Italia A, Gresele P, Morser J, et al. (2001) Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 85: 661–666.

39. Dwork U (2006) Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 26: 1463–1478.

40. te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes IH, et al. (2003) Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 1: 2087–2096.

41. Bedersen JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, et al. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472–476.

42. Moran PM, Higgins LS, Cordell B, Moser PC (1995) Age-related learning impairment in the 5-, 9-, and 12-month-old rat. J Gerontol B Psychol Sci Soc Sci 50: 127–132.

43. Connolly ES, Jr., Winfree CJ, Stern DM, Solomon RA, Pinsky DJ (1996) Carboxypeptidase U is a potential regulator of vascular inflammation during the acute and convalescent phase of ischemic stroke. Blood 88: 2329–2334.

44. O’Collins VE, Macleod MR, Donnan GA, Horky LL, Van der Worp BH, et al. (2008) Efficacy and safety of thrombolytic treatment in acute ischemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 372: 1275–1282.

45. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, et al. (2008) Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 39: 929–934

46. Van der Worp HB, de Haan P, Morrema E, Kalkman CJ (2005) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94: 811–818.